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Abstract
Objectives: It has been reported that the mortality risk for heart failure differs between men and
women. It has been postulated that this is due to differences in comorbid features. Variation in risk pro-
files by gender may limit the performance of stratification algorithms available for heart failure in
women. This analysis examined the ability of a published risk stratification model to predict outcomes in
women.
Methods: The Acute Decompensated Heart Failure National Registry Emergency Module (ADHERE-
EM) database was used. Characteristics, treatments, and outcomes for men and women were compared.
The ADHERE registry classification and regression tree (CART) analysis was used for the risk stratifica-
tion evaluation.
Results: Of 10,984 ADHERE-EM patients, 5,736 (52.2%) were women. In-hospital mortality was similar
between men and women (p = 0.727). Significant differences (p < 0.0002) were noted by gender in all
three variables in the CART model (blood urea nitrogen [BUN] ‡ 43 mg ⁄ dL, systolic blood pressure
< 115 mm Hg, and serum creatinine ‡ 2.75 mg ⁄ dL). However, the CART model effectively stratified both
genders into distinct risk groups with no significant difference in mortality by gender within stratified
groups.
Conclusions: The ADHERE Registry CART tool is effective at predicting risk in ED patients, regardless
of gender.
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INTRODUCTION
C ardiovascular disease is the leading cause ofdeath in women, with heart failure being amajor cause of death and disability in this popu-
lation.1 Women have a lifetime risk of developing heart
failure equal to that of men, estimated at one in five.2,3
Hospitalizations for heart failure are common, with
1,092,000 primary heart failure discharge diagnoses
reported in 2004.4 Of these discharges, 520,000 (48%)
occurred in men and 571,000 (52%) in women. In com-
parison, there were 309,000 discharges for myocardial
infarction in women.4
Despite the significant number of women hospitalized
for acute decompensated heart failure (ADHF), the clin-
ical characteristics, treatments, outcomes, and risk pro-
files of these women are inadequately understood,
particularly in the emergency setting. Analyses of gen-
der differences in heart failure have primarily origi-
nated from clinical trial databases. However, women
comprise only about 20% of the enrollment in heart
failure clinical trials.5,6 Thus, robust conclusions regard-
ing gender differences in heart failure cannot be drawn
from these datasets.
Treatment disparities in women compared to men
have been reported in other areas of cardiovascular
disease.7–9 Gender differences in treatment approaches
may also be present among patients with ADHF in the
emergency setting, but this hypothesis has not been
examined in a large, representative data set. Prior stud-
ies have established that the pathophysiology, demo-
graphics, and presentation characteristics of women
with heart failure are different from men, but it is not
clear that these differences influence therapeutic selec-
tion or clinical outcome in the acute setting.10–22 In
addition, several studies have identified clinical vari-
ables that predict short-term mortality in patients with
ADHF, but it is not known whether these prognostic
markers ascertain risk equally in men and women.23–29
It is plausible that risk factors for mortality may be
disparate in men and women because of gender
differences in heart failure characteristics or patho-
physiology.
We used the Acute Decompensated Heart Failure
National Registry Emergency Module (ADHERE-EM)
database to evaluate gender differences in the presenta-
tion, treatment, and outcome of patients with ADHF in
the emergency department (ED). Analyses were also
performed to ascertain differences in the prevalence of
established risk factors according to gender and to
evaluate the ability of a previously described risk strati-
fication tool to predict mortality in both men and
women in the emergency setting.24
METHODS
Study Design
This was a retrospective chart review to examine the
ability of a published risk-stratification model to predict
outcomes in women. All hospitals obtained institutional
review or ethics board approval for participation. The
data collection system was designed such that patient
informed consent was not required.30
Study Setting and Population
The ADHERE-EM database was created as part of the
ADHERE registry program, and patients were enrolled
between January 2004 and September 2005. ADHERE
is a large, national, multicenter registry designed to col-
lect data on the demographics, clinical characteristics,
treatment patterns, and outcomes of patients hospital-
ized for ADHF.30 The data were collected at 83 hospi-
tals, including 53 academic centers. The goal of
ADHERE-EM was to specifically characterize the initial
ED evaluation, treatment, and subsequent inpatient
management of patients presenting to the ED with
ADHF. Therefore, the ADHERE-EM contains detailed
data regarding the initial ED presentation, treatment,
and disposition not contained in the ADHERE registry.
This cohort also included all patients presenting to the
ED and identified as having a diagnosis of ADHF
regardless of their final disposition.
The registry entries consisted of all consecutive adult
patients with either an ED or a hospital discharge diag-
nosis of ADHF, ADHF that was determined to be clini-
cally present by the patient care team, or ADHF as
documented in the diagnosis-related group (DRG) code
or ambulatory procedure code. The diagnosis of ADHF
was based on the DRG in admitted patients. ADHF had
to be the focus of treatment for the patient to be
included. Importantly, registry participation did not
require any alteration of treatment or ED care, and
entry of data into the registry was not contingent on
the use of any particular therapeutic agent or treatment
regimen. Hospitals of various sizes throughout the Uni-
ted States were represented, and both academic and
community hospitals were included.
Measures
Demographic, medical history, clinical presentation,
laboratory, treatment course, and clinical outcome data
were collected and entered into a Health Insurance Por-
tability and Accountability Act of 1996 (HIPAA)-compli-
ant Web-based electronic data capture system using an
electronic case report form. Patient identifiers were not
collected.
Data Analysis
Descriptive statistics were used to describe gender dif-
ferences in presentation, demographics, treatments,
and laboratory values. A logistic regression model
adjusting for baseline covariates that have previously
been shown in the main ADHERE registry to be associ-
ated with mortality (blood urea nitrogen [BUN], systolic
blood pressure [sBP], serum creatinine [SCr], age, and
dyspnea at rest)24 was performed.
For the risk stratification analysis, patients were cate-
gorized according to the five risk groups identified by
the previously derived and validated classification and
regression tree (CART) analysis of the main ADHERE
registry: high risk (BUN ‡ 43 mg ⁄ dL, sBP < 115 mm Hg,
and SCr ‡ 2.75 mg ⁄ dL); intermediate risk 1 (BUN ‡ 43
mg ⁄ dL, sBP < 115 mm Hg, and SCr < 2.75 mg ⁄ dL);
intermediate risk 2 (BUN ‡ 43 mg ⁄ dL and sBP
‡ 115 mm Hg); intermediate risk 3 (BUN < 43 mg ⁄ dL
and sBP < 115 mm Hg); and low risk (BUN < 43 mg ⁄ dL
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and sBP ‡ 115 mm Hg).24 A complete case analysis was
performed. The predictive value of this model was then
assessed by determination of mortality odds ratios
(ORs) and 95% confidence intervals (CIs) between risk
groups for men and women. These analyses were per-
formed using Version 8.2 of SAS software (SAS Insti-
tute, Inc., Cary, NC).
RESULTS
A total of 10,984 patient records were available in the
ADHERE-EM database. Of these, 5,248 (47.8%) were
men and 5,736 (52.2%) were women. Heart failure was
the primary discharge diagnosis in 97%, and 83% had
heart failure as the ED admitting diagnosis. The mean
age of the overall patient population was 73.1 years,
and men were younger than women (Table 1). In the
overall patient population, 76% had a prior history of
heart failure, 45% had a history of diabetes, and 79%
had a history of hypertension. A slightly higher propor-
tion of men had a history of heart failure or diabetes,
and more women had a history of hypertension. Pre-
served systolic function was present in a significantly
greater proportion of women compared to men
(Table 1).
In-hospital outcomes and procedures were similar
among men and women (Figure 1). In-hospital mortality
was 3% for men and 2.8% for women (OR 1.04, 95%
CI = 0.83 to 1.30). The risk of death was similar between
men and women after adjusting for covariates (OR 1.10,
95% CI = 0.86 to 1.40). No gender differences were
present in other important in-hospital clinical
Table 1
Baseline Characteristics
Demographics Men (n = 5,248) Women (n = 5,736) p-Value
Age, years (SD) 70.2 (14.4) 75.7 (14.2) <0.0001
Race, n (%)
White 3,629 (69.2) 4,091 (71.3) 0.0299
African American 1,144 (21.8) 1,172 (20.4)
Asian 28 (0.5) 34 (0.6)
Hispanic 165 (3.1) 136 (2.4)
Other 53 (1.0) 52 (0.9)
Unknown 229 (4.4) 251 (4.4)
Comorbidities
Prior heart failure, n (%) 4,049 (77) 4,326 (75) 0.0328
LVEF
Mean (SD) 34 (15.6) 42.9 (17.1) <0.0001
<40, n (%) 2,753 ⁄ 4,455 (61.8) 1,884 ⁄ 4,776 (39.4) <0.0001
Atrial fibrillation, n (%) 1,659 (32) 1,888 (33) 0.1447
Hypertension, n (%) 4,065 (77) 4,650 (81) <0.0001
Diabetes, n (%) 2,402 (46) 2,518 (44) 0.0488
COPD ⁄ asthma, n (%) 1,818 (35) 1,863 (32) 0.0165
Chronic dialysis, n (%) 403 (8) 442 (8) 0.9407
Clinical presentation
Dyspnea at rest, n (%) 1,831 (34.9) 2,051 (35.8) 0.3423
Edema, n (%) 3,417 (65.1) 3,540 (61.7) 0.0002
Rales, n (%) 3,180 (60.6) 3,608 (62.9) 0.01
Elevated JVP, n (%) 1,066 (35.6) 1,057 (31.2) 0.0002
Fatigue, n (%) 1,338 (25.5) 1,603 (27.9) 0.004
sBP
mm Hg (SD) 143.4 (32.9) 149.9 (33.9) <0.0001
>140 mm Hg, n (%) 2,585 (49.4) 3,346 (58.5) <0.0001
<115 mm Hg, n (%) 1,019 (19.5) 844 (14.8) <0.0001
Heart rate, beats ⁄ min (SD) 89.2 (21.6) 89.7 (22.6) 0.22
Oxygen saturation, % (SD) 94.4 (5.7) 93.8 (6.3) <0.0001
Chest x-ray congestion, n (%) 3,684 (72.4) 4,163 (74.8) 0.004
Laboratory measures
BNP, pg ⁄ mL (SD) 1,260.6 (1136) 1,204.3 (1114.5) 0.03
BUN*
mg ⁄ dL (SD) 31.1 (20) 29.3 (18.5) <0.0001
mmol ⁄ L (SD) 11.1 (7.1) 10.5 (6.6)
‡43 mg ⁄ dL, n (%) 1,080 (20.9) 1,026 (18.1) 0.0003
SCr
mg ⁄ dL (SD) 1.9 (1.7) 1.7 (1.5)
lmol ⁄ L (SD) 168 (150.3) 150.3 (132.6) <0.0001
‡2.75 mg ⁄ dL, n (%) 619 (11.9) 550 (9.7) 0.0002
Troponin I, lg ⁄ L (SD) 0.2 (1.3), n = 2,913 0.4 (6.2), n = 3,179 0.22
Troponin T, lg ⁄ L (SD) 0.2 (2.6), n = 715 0.1 (0.5), n = 768 0.28
Dichotomous variables are reported as n (%), and continuous variables are reported as mean (SD).
COPD = chronic obstructive pulmonary disease; LVEF = left ventricular ejection fraction; JVP ¼ jugular venous pressure;
sBP ¼ systolic blood pressure; BNP ¼ B-type natriuretic peptide; BUN ¼ blood urea nitrogen; SCr ¼ serum creatinine.
*To convert from mmol ⁄ L to mg ⁄ dL, divide by 0.357.
To convert from lmol ⁄ L to mg ⁄ dL, divide by 88.4.
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procedures, including dialysis or need for mechanical
ventilation.
The decision tree generated by CART analysis cate-
gorized men and women into high-, intermediate-, and
low-risk groups (Figure 2). In the study cohort, 98.5%
of all subjects had complete data and were included in
the analysis. The clinical characteristics of the five
groups by gender are shown in Table 2. Patients in the
higher risk groups tended to be older and diabetic and
have systolic dysfunction compared to patients in the
lower risk groups.
Differences were observed in the proportion of men
and women at each risk node. Women were more likely
to be in the lowest risk node (OR 1.3, 95% CI = 1.2 to
1.4), while men were more likely to be in the highest
risk node (OR 1.7, 95% CI = 1.2 to 2.4). No significant
difference in the rate of mortality by gender was
detected within risk categories (Table 3). The risk cate-
gorization method stratified in-hospital mortality risk
regardless of gender. The mortality OR between the
high- and low-risk groups was 9.3 (95% CI = 4.2 to
20.3, p < 0.0001) in women and 8.6 (95% CI = 4.0 to
18.1, p < 0.0001) in men (Table 2). Discrimination
between the intermediate-risk and the high-risk group
was not as robust.
DISCUSSION
This analysis of the ADHERE-EM registry in ED
patients revealed several gender disparities in ADHF
clinical characteristics and treatment patterns. Despite
these differences, a previously validated risk stratifica-
tion tool showed good dispersion of risk in both men
and women.
Figure 1. In-hospital outcomes by gender. ( ) Men; (h) women.
ADHERE-EM patients
BUN < 43 mg/dL BUN ≥ 43 mg/dL
sBP < 115 mmHg
Intermediate Risk 2
Male Mortality
n = 40 (5.2%)
Female Mortality
n = 37 (4.6%) 
sBP ≥ 115 mmHg
Low Risk
Male Mortality
n = 45 (1.3%)
Female Mortality
n = 69 (1.7%)
sBP < 115
mm Hg
sBP ≥ 115 mmHg
Intermediate Risk 3
Male Mortality
n = 27 (3.8%)
Female Mortality
n = 28 (4.4%) 
SCr < 2.75 mg/dL
Intermediate Risk 1
Male Mortality
n = 32 (14.3%)
Female Mortality
n = 19 (12.4%)
SCr ≥ 2.75 mg/dL
High Risk
Male Mortality
n = 9 (10.3%)
Female Mortality
n = 8 (14.0%)
Figure 2. Predictors of in-hospital mortality and risk stratification. ADHERE-EM ¼ Acute Decompensated Heart Failure National
Registry Emergency Module; BUN ¼ blood urea nitrogen; sBP ¼ systolic blood pressure; SCr ¼ serum creatinine.
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Our analysis generated evidence to suggest that
in-hospital mortality was not different in men and
women at any level of predicted risk based on admis-
sion variables. This finding is clinically significant
because previous reports have suggested that female
gender is associated with a lower mortality risk.31–38
These previous studies were largely based on clinical
trial data sets in the chronic heart failure population,
and women have generally been underrepresented in
clinical trials.5,6 In contrast, the ADHERE-EM registry
population was 52% women, a factor that enhances the
generalizability of our analysis. Consistent with our
findings, gender has not been shown to independently
predict mortality in other large, representative data
sets.24,25,39 The finding that women have an in-hospital
mortality risk similar to that of men has important clini-
cal implications. These data suggest that patients hospi-
talized with ADHF should receive optimal, evidence-
based therapy and appropriate monitoring irrespective
of gender. The CART tool, previously developed and
validated by Fonarow et al.,24 effectively predicted in-
hospital mortality in both men and women across all
risk categories in the ADHERE-EM data set. The ability
to accurately risk-stratify patients with ADHF in the ED
is critical to ensuring appropriate resource utilization
and early implementation of an appropriate therapeutic
plan. In addition, utilizing a tool that has good risk dif-
ferentiation in both men and women may minimize
treatment bias attributed to gender.
Systolic blood pressure, SCr, and BUN have been
shown in previous models to predict outcome.23–25,40,41
The predictive risk was not stratified by gender in these
analyses. It is plausible that prognostic markers may be
gender-specific because of significant differences
between men and women in heart failure etiology, path-
ophysiology, or the prevalence of predictor variables.
This has been shown with B-type natriuretic peptide lev-
els. In patients with acute dyspnea, B-type natriuretic
peptide values > 500 pg ⁄ mL displayed a higher rate of
mortality at 24 months in women compared to men
(68% vs. 46%, p = 0.015).42 In addition, women with
heart failure tend to be older, and they have higher rates
of hypertension and preserved systolic function.43–45
Women also tend to present with ischemic heart disease
less often.32 In one study of 5,491 patients admitted with
heart failure, women were more likely than men to have
a creatinine clearance < 60 mL ⁄ minute and a higher left
ventricular ejection fraction (LVEF).36 Data from the
ADHERE registry showed that fewer women than men
had SCr > 2.0 mg ⁄ dL, elevated BUN, or low sBP.5,39 Dif-
ferences in the presence of low sBP, SCr ‡ 2.75 mg ⁄ dL,
and BUN ‡ 43 mg ⁄ dL were noted between men and
women in this study.
Despite the observed gender differences in the preva-
lence of discriminatory variables, the CART-derived
model was able to stratify risk in men and women to a
similar degree. This model performed well in a diverse
ED patient population with ADHF identifying a high-
and low-risk group, and it also provided useful
information independent of gender. This study provides
evidence that a model using discriminatory parameters
readily available in the ED can be used in conjunction
with clinical judgment to identify both men and women
who are at highest risk of short-term mortality and
who may benefit from a high level of care. In particular,
it identified those subjects at either end of the spectrum
of risk, which may have the greatest impact on clinical
care.
LIMITATIONS
This analysis should be interpreted in the context of
several limitations. First, we analyzed episodes of ED
presentations and hospitalizations, not unique patients.
The treatment differences noted in women with ADHF
during the acute management, in-hospital, or discharge
time points cannot be solely attributed to disparities in
care. Gender-specific variations in pathophysiology,
reported symptoms, or preservation of systolic function
may require divergent treatment strategies that are
clinically appropriate. In addition, the patient’s
response to the initial diuretic administration was not
collected in the database. The data for this analysis
were collected by retrospective chart review, and this
Table 2
In-hospital Mortality between Risk Groups
Females Males
OR (95% CI) p-Value OR (95% CI) p-Value
High vs.
Low 9.3 (4.2, 20.3) <0.0001 8.6 (4.0, 18.1) <0.0001
Intermediate 3 3.6 (1.5, 8.2) 0.0016 2.9 (1.3, 6.4) 0.006
Intermediate 2 3.4 (1.5, 7.7) 0.0018 2.1 (1.0, 4.5) 0.052
Intermediate 1 1.2 (0.5, 2.8) 0.756 0.69 (0.31, 1.5) 0.35
Intermediate 1 vs.
Low 8.1 (4.7, 13.8) <0.0001 12.4 (7.7, 20.0) <0.0001
Intermediate 3 3.1 (1.7, 5.7) 0.0002 4.2 (2.5, 7.2) <0.0001
Intermediate 2 3.0 (1.7, 5.3) 0.0001 3.0 (1.9, 5.0) <0.0001
Intermediate 2 vs.
Low 2.7 (1.8, 4.1) <0.0001 4.1 (2.7, 6.3) <0.0001
Intermediate 3 1.0 (0.6, 1.7) 0.8641 1.4 (0.8, 2.3) 0.19
Intermediate 3 vs. low 2.6 (1.7, 4.1) <0.0001 3.0 (1.8, 4.8) <0.0001
OR ¼ odds ratio; CI ¼ confidence interval.
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methodology may not reflect the treating physician’s
interpretation of symptom severity or acuity, a factor
that likely influences treatment. The DRG code was uti-
lized in admitted patients to identify eligible subjects. It
is possible that these subjects were not identified as
having ADHF in the ED. In addition, the physician’s
assessment of risk was not obtained; thus, we cannot
evaluate the contribution of the risk model above clini-
cal assessment alone. While we observed an association
between gender and the ED administration of some
therapies, we cannot ascertain from these data whether
or not gender was a causative factor in these treatment
differences.
This analysis was based on the assumption that dis-
criminatory variables did not differ between the
ADHERE-EM and ADHERE core databases. However,
the current model defined five distinct categories of
risk, suggesting that discriminatory variables were
appropriately applied. The intent of this analysis was to
identify those at highest risk of death, and therefore in
greatest need of aggressive monitoring and care, rather
than to determine patients suitable for discharge to
home. However, the sample size in the final nodes is
small, with wide CIs, therefore limiting the stability of
the stratification model. Finally, sites participating in
the ADHERE-EM registry were experienced in the
management of ADHF, and their treatment approaches
may not reflect those of general ED settings.
CONCLUSIONS
We noted variations in clinical parameters included in
the CART risk stratification model in women compared
to men, in this study of more than 10,000 patients pre-
senting to the ED with ADHF. Women have a risk of
in-hospital mortality similar to men, and a risk stratifi-
cation model accounting for sBP, BUN, and SCr pre-
dicted risk similarly between genders. More research is
needed to fully understand potential gender differences
in ADHF, and future trials should aim to enroll a repre-
sentative sample of women so that important clinical
questions in this population can be addressed.
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